






**Figure 2: G-cleaver Motif**



**Figure 3: Chemically Stabilized Zinzyme Motif**




**Figure 4. Chemically Stabilized Amberzyme Motif**



The gaa loops may be replaced with loops of differing nucleic acid compositions, or with a linker, for example an 18 atom polyethylene glycol (Spacer) or equivalent.

Phosphorothioate linkages can be introduced, for example, at the 4' terminal 5'-internucleotide linkages, to increase nuclease stability.


Figure 5: DNAzyme Motif




Legend

Y = U or C  
R = A or G


**FIGURE 6** *Dual Reporter System for Cytoplasmic HCV Target*



**Figure 7: Secondary structure of the HCV 5'UTR**




**Figure 8: A Chemically Stabilized Enzymatic Nucleic Acid Molecule**




UPPER CASE = RIBO nucleotide  
lower case = 2'-O-methyl nucleotide  
u = 2'-deoxy-2'-amino Uridine  
s = phosphorothioate  
B = inverted deoxybasic moiety



**Figure 9: Enzymatic nucleic acid mediated inhibition of HCV-luciferase expression**




**Figure 9: Enzymatic nucleic acid mediated inhibition of HCV-luciferase expression**




**Figure 10: Dose-dependent enzymatic nucleic acid inhibition of HCV/luciferase expression**

**A.**




**Figure 10: Dose-dependent enzymatic nucleic acid inhibition of HCV/luciferase expression**

**B.**




**Figure 10: Dose-dependent enzymatic nucleic acid inhibition of HCV/luciferase expression**

C.




**Figure 10: Dose-dependent enzymatic nucleic acid inhibition of HCV/luciferase expression**

**D.**




**Figure 10: Dose-dependent enzymatic nucleic acid inhibition  
of HCV/luciferase expression**

**E.**



**Figure 11: Enzymatic nucleic acid reduction of HCV/luciferase RNA and inhibition of HCV-luciferase expression**


**A.**






**Figure 11: Enzymatic nucleic acid reduction of HCV/luciferase RNA and inhibition of HCV-luciferase expression**

**B.**




**Figure 12: Interferon Dose response with Enzymatic Nucleic Acid**




**A.**

**Figure 12: Interferon Dose response with Enzymatic Nucleic Acid**




**B.**


**Figure 13: Site 195 anti-HCV enzymatic nucleic acid dose response in combination with interferon pretreatment**




**Figure 14A: CIFN dose response with site 195 anti-HCV enzymatic nucleic acid treatment**




**Figure 14B: Site 195 anti-HCV enzymatic nucleic acid dose response with CIFN pretreatment**



**Figure 15: Enhanced antiviral effect of an anti-HCV enzymatic nucleic acid targeting site 195 used in combination with consensus interferon (CIFN)**



**Figure 16: Inhibition of HCV-PV Replication  
by Zinzyme Treatment**





**Figure 17: Inhibition of HCV-Poliovirus Replication by Antisense**

